floxuridine has been researched along with Carcinoma, Renal Cell in 33 studies
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
Carcinoma, Renal Cell: A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Using a murine dorsal air sac (DAS) assay, we have previously shown that UFT and its metabolites, gamma-hydroxybutyric acid (GHB) and 5-fluorouracil (5-FU), inhibited the angiogenesis induced by murine renal cell carcinoma." | 3.71 | gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. ( Aoyagi, K; Basaki, Y; Chikahisa, L; Hashimoto, A; Miyadera, K; Okabe, S; Wierzba, K; Yamada, Y; Yonekura, K, 2001) |
| "Floxuridine dosages were escalated to a maximum of 0." | 2.69 | Continuous-infusion floxuridine and alpha interferon in metastatic renal cancer: a national biotherapy study group phase II study. ( Church, CK; DePriest, CB; Honeycutt, PJ; Schulof, RS; Soori, GS; Stark, JJ; Wiemann, MC, 1999) |
| "Metastatic renal cell carcinoma patients with measurable disease entered the study." | 2.68 | Treatment of metastatic renal cell carcinoma with constant-rate floxuridine infusion plus recombinant alpha 2b-interferon. ( Brunetti, I; Cianci, C; Conte, PF; Falcone, A; Giulianotti, PC; Lencioni, M; Mosca, F; Pfanner, E; Ricci, S; Vannucci, L, 1996) |
| "Metastatic renal cell carcinoma (RCC) is largely chemoresistant." | 2.67 | A phase I/II study of alternating constant rate infusion floxuridine with constant rate infusion vinblastine for the treatment of metastatic renal cell carcinoma. ( Carroll, PR; Ernest, ML; Frye, JW; Small, EJ; Stagg, RJ; Wilkinson, MJ, 1994) |
| "The initial dosage was 0." | 2.67 | A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma. ( Carroll, PR; Ernest, ML; Frye, JW; Small, EJ; Stagg, RJ; Venook, AP; Wilkinson, MJ, 1993) |
| "Therapy of metastatic bladder cancer with doxorubicin-cisplatin was made more tolerable by this same circadian approach resulting in a 57% objective response rate." | 2.41 | Circadian chemotherapy for gynecological and genitourinary cancers. ( Hrushesky, WJ; Kobayashi, M; Wood, PA, 2002) |
| "Metastatic renal cell carcinoma has a poor prognosis, requiring systemic therapy, in addition to radical nephrectomy." | 1.30 | Chemotherapy with FUDR in the management of metastatic renal cell carcinoma. ( Aveta, P; Cracco, C; Neira, D; Rocca Rossetti, S; Terrone, C, 1997) |
| "The authors treated 10 advanced renal cell carcinoma with circadian venous continuous infusion of 5-Fluoro 2-Deoxyuridine (FUDR)." | 1.28 | [Adjuvant chemotherapy]. ( Buzzetti, V; Cogni, M; Del Nero, A; Longo, G; Mandressi, A; Mangiarotti, B; Russo, R, 1991) |
| "A total of 42 patients with metastatic renal cell carcinoma received floxuridine infusion for 14 days at monthly intervals." | 1.28 | Circadian infusion of floxuridine in patients with metastatic renal cell carcinoma. ( Amato, R; Dexeus, FH; Kilbourn, R; Kwan, J; Logothetis, CJ; Newman, RA; Ogden, S; Sella, A; Striegel, A, 1991) |
| "The authors treated 42 metastatic renal cell carcinoma (RCC) patients who had received no previous chemotherapy or radiation therapy with circadian venous continuous infusion of 5-fluoro-2-deoxyuridine (FUDR)." | 1.28 | Circadian continuous chemotherapy of renal cell carcinoma with an implantable, programmable infusion pump. ( Bonalumi, MG; Comeri, G; Damascelli, B; Del Nero, A; Garbagnati, F; Lutman, R; Marchianò, A; Mauri, M; Salvetti, M; Spreafico, C, 1990) |
| "Our results indicate that metastatic renal cell cancer responds to infusional chemotherapy and that the circadian shape of infusion markedly affects our ability to deliver effective doses." | 1.27 | Circadian-based infusional chrono-chemotherapy controls progressive metastatic renal cell carcinoma. ( Fraley, EE; Hrushesky, WJ; Rabatin, JT; Von Roemeling, R, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (9.09) | 18.7374 |
| 1990's | 21 (63.64) | 18.2507 |
| 2000's | 9 (27.27) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, HJ | 1 |
| Wang, H | 1 |
| Li, HZ | 1 |
| Shi, BB | 1 |
| Song, ZL | 1 |
| Stadler, WM | 2 |
| Ikemoto, S | 1 |
| Sugimura, K | 1 |
| Yoshida, N | 1 |
| Kuratsukuri, K | 1 |
| Wada, S | 1 |
| Nakatani, T | 1 |
| Gore, ME | 1 |
| Escudier, B | 1 |
| Chu, SI | 1 |
| Kim, HJ | 1 |
| Skubitz, KM | 1 |
| Wong, MK | 1 |
| Bjarnason, GA | 2 |
| Hrushesky, WJ | 8 |
| Webster, P | 1 |
| Morava-Protzner, I | 1 |
| Towers, M | 1 |
| Small, EJ | 3 |
| Frye, JW | 2 |
| Wilkinson, MJ | 2 |
| Carroll, PR | 2 |
| Ernest, ML | 2 |
| Stagg, RJ | 2 |
| Falcone, A | 2 |
| Cianci, C | 2 |
| Ricci, S | 2 |
| Brunetti, I | 2 |
| Bertuccelli, M | 1 |
| Conte, PF | 2 |
| Conroy, T | 1 |
| Geoffrois, L | 1 |
| Guillemin, F | 1 |
| Luporsi, E | 1 |
| Krakowski, I | 1 |
| Spaëth, D | 1 |
| Frasie, V | 1 |
| Volff, D | 1 |
| Venook, AP | 1 |
| Doyle, N | 1 |
| Sone, M | 1 |
| Beattie, K | 1 |
| Elia, J | 1 |
| Owens, B | 1 |
| Garufi, C | 1 |
| Lévi, F | 1 |
| Giunta, S | 1 |
| Aschelter, A | 1 |
| Pace, R | 1 |
| Nisticò, C | 1 |
| Terzoli, E | 1 |
| Pfanner, E | 1 |
| Lencioni, M | 1 |
| Giulianotti, PC | 1 |
| Vannucci, L | 1 |
| Mosca, F | 1 |
| Aveta, P | 1 |
| Terrone, C | 1 |
| Neira, D | 1 |
| Cracco, C | 1 |
| Rocca Rossetti, S | 1 |
| Hirano, Y | 2 |
| Takayama, T | 2 |
| Ushiyama, T | 2 |
| Suzuki, K | 2 |
| Fujita, K | 2 |
| Soori, GS | 1 |
| Schulof, RS | 1 |
| Stark, JJ | 1 |
| Wiemann, MC | 1 |
| Honeycutt, PJ | 1 |
| Church, CK | 1 |
| DePriest, CB | 1 |
| Yonekura, K | 2 |
| Basaki, Y | 2 |
| Chikahisa, L | 2 |
| Okabe, S | 2 |
| Hashimoto, A | 2 |
| Miyadera, K | 2 |
| Wierzba, K | 2 |
| Yamada, Y | 2 |
| Reese, DM | 1 |
| Corry, M | 1 |
| Morita, T | 1 |
| Matsuzaki, A | 1 |
| Tokue, A | 1 |
| Aoyagi, K | 1 |
| Kobayashi, M | 1 |
| Wood, PA | 1 |
| Kageyama, S | 1 |
| Vogelzang, NJ | 1 |
| Vokes, EE | 1 |
| Charette, J | 1 |
| Whitman, G | 1 |
| Del Nero, A | 2 |
| Mandressi, A | 1 |
| Longo, G | 1 |
| Cogni, M | 1 |
| Mangiarotti, B | 1 |
| Buzzetti, V | 1 |
| Russo, R | 1 |
| Dexeus, FH | 1 |
| Logothetis, CJ | 1 |
| Sella, A | 1 |
| Amato, R | 1 |
| Kilbourn, R | 1 |
| Ogden, S | 1 |
| Striegel, A | 1 |
| Kwan, J | 1 |
| Newman, RA | 1 |
| Damascelli, B | 2 |
| Marchianò, A | 2 |
| Frigerio, LF | 1 |
| Salvetti, M | 2 |
| Spreafico, C | 2 |
| Garbagnati, F | 2 |
| Zanoni, F | 1 |
| Radice, F | 1 |
| Lutman, R | 1 |
| Bonalumi, MG | 1 |
| Mauri, M | 1 |
| Comeri, G | 1 |
| von Roemeling, R | 4 |
| Lanning, RM | 1 |
| Rabatin, JT | 3 |
| Fraley, EE | 2 |
3 reviews available for floxuridine and Carcinoma, Renal Cell
| Article | Year |
|---|---|
Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II | 2006 |
Circadian chemotherapy for gynecological and genitourinary cancers.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Cycle; Chronotherapy; Circadian Rhythm; | 2002 |
The multifrequency (circadian, fertility cycle, and season) balance between host and cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Renal Cell; Circadian Rhythm; Female; F | 1991 |
13 trials available for floxuridine and Carcinoma, Renal Cell
| Article | Year |
|---|---|
[Immunotherapy of metastatic renal cell carcinoma: report of 28 cases].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal | 2004 |
A phase I/II study of alternating constant rate infusion floxuridine with constant rate infusion vinblastine for the treatment of metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Administrat | 1994 |
Alpha-2B-interferon plus floxuridine in metastatic renal cell carcinoma. A phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Floxurid | 1993 |
Simplified chronomodulated continuous infusion of floxuridine in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Circadian Rhythm; Drug Administration Schedul | 1993 |
A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Circadian Rhythm; Diarrhea; Drug Administrati | 1993 |
Chronomodulated 5-day infusion of floxuridine and L-folinic acid in patients with advanced malignancies: a feasibility and tolerability study.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Chronobiology Phenom | 1995 |
Treatment of metastatic renal cell carcinoma with constant-rate floxuridine infusion plus recombinant alpha 2b-interferon.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Administrat | 1996 |
Continuous-infusion floxuridine and alpha interferon in metastatic renal cancer: a national biotherapy study group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cel | 1999 |
Continuous-infusion fluorodeoxyuridine with leucovorin and high-dose interferon: a phase II study in metastatic renal-cell cancer.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carci | 1992 |
Flexibility and efficacy of automatic continuous fluorodeoxyuridine infusion in metastases from a renal cell carcinoma.
Topics: Brain Neoplasms; Carcinoma, Renal Cell; Circadian Rhythm; Drug Administration Schedule; Drug Evaluat | 1991 |
Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma.
Topics: Adult; Aged; Carcinoma, Renal Cell; Circadian Rhythm; Female; Floxuridine; Humans; Infusion Pumps; K | 1990 |
Cancer chronotherapy: a drug delivery challenge.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Circadian Rhythm; Colorectal Neoplasms; Drug | 1990 |
Circadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer.
Topics: Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Implants | 1989 |
17 other studies available for floxuridine and Carcinoma, Renal Cell
| Article | Year |
|---|---|
Cytotoxic chemotherapy for metastatic renal cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Clinical Trials | 2004 |
Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with interferon-alpha in renal cell carcinoma cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Ce | 2004 |
Pulmonary toxicity of continuous infusion 5-fluoro-2'-deoxyuridine.
Topics: Aged; Carcinoma, Renal Cell; Floxuridine; Humans; Infusions, Intravenous; Kidney Neoplasms; Lung Dis | 1995 |
Steroid-responsive interstitial lung disease in patients receiving 2'-deoxy-5-fluorouridine-infusion chemotherapy. A report of three cases.
Topics: Aged; Carcinoma, Renal Cell; Cough; Dyspnea; Female; Fever; Floxuridine; Forced Expiratory Volume; H | 1995 |
Formal clinical evaluation of the CADD-Micro system for circadian delivery of FUDR in patients with metastatic renal cell cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Circadian Rhythm; Drug Administration Schedu | 1995 |
Chemotherapy with FUDR in the management of metastatic renal cell carcinoma.
Topics: Actuarial Analysis; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Chemotherap | 1997 |
[The correlation between thymidine phosphorylase activity of renal cancer cells and the chemosensitivity to 5-FU and 5'-DFUR].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Screening Assays | 1998 |
UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice.
Topics: 4-Butyrolactone; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cel | 1999 |
Infusional floxuridine-based therapy for patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2000 |
Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Cell Survival; Deoxyc | 2001 |
gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma; Carc | 2001 |
Thymidine phosphorylase activity in renal cell carcinoma: relationship between histological parameters and chemosensitivity to fluorouracil-related drugs.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Floxuridine; Fluorouracil; Humans; Kidney; K | 2002 |
[Adjuvant chemotherapy].
Topics: Adult; Aged; Carcinoma, Renal Cell; Drug Administration Schedule; Floxuridine; Follow-Up Studies; Hu | 1991 |
Circadian infusion of floxuridine in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Floxuridine; Humans; Infus | 1991 |
Circadian continuous chemotherapy of renal cell carcinoma with an implantable, programmable infusion pump.
Topics: Adult; Aged; Carcinoma, Renal Cell; Drug Evaluation; Female; Floxuridine; Humans; Infusion Pumps, Im | 1990 |
Progressive metastatic renal cell carcinoma controlled by continuous 5-fluoro-2-deoxyuridine infusion.
Topics: Adult; Aged; Carcinoma, Renal Cell; Female; Floxuridine; Gastrointestinal Diseases; Humans; Infusion | 1988 |
Circadian-based infusional chrono-chemotherapy controls progressive metastatic renal cell carcinoma.
Topics: Adult; Aged; Carcinoma, Renal Cell; Circadian Rhythm; Dose-Response Relationship, Drug; Female; Flox | 1988 |